15 Jun Adolescents With Migraine Benefit from Combination Medication
Adolescents who suffer from migraine may find relief with a combination of sumatriptan and naproxen sodium (suma/nap), according to a study published online last month in Pediatrics.
Researchers studied 600 teens, ages 12 to 17, who experienced two to eight migraine attacks per month for at least six months. The first migraine during the study period was treated with a placebo. If the pain persisted two hours later, the teens were assigned to a placebo group or to a group receiving different doses of suma/nap: 10/60 mg, 30/180 mg or 85/500 mg. Researchers then evaluated who was pain-free two hours later.
All subjects who received active medication benefited, with similar two-hour pain-free results. In the 10/60 mg group, 29% were pain-free, compared with 27% in the 30/180 mg group, 24% in the 85/500 mg group and 10% in the placebo group.
“All doses of suma/nap were well tolerated, providing similarly effective acute treatment of adolescent migraine pain and associated symptoms, as compared with placebo,” the authors wrote.
Note: Several of the researchers disclosed financial ties to pharmaceutical companies, including lead author Frederick J. Derosier, DO, from GlaxoSmithKline in Research Triangle Park, North Carolina. GlaxoSmithKline funded the study and manufactures sumatriptan and naproxen sodium.